On this page

What is Steatorrhea?
How Dietary Fats Are Normally Absorbed
Causes
Symptoms
Complications
Diagnosis
Treatment
Frequently Asked Questions
Sources and Bibliography

What is Steatorrhea?

Steatorrhea is the presence of an excessive amount of fat in the stools. It occurs when dietary fats, for one reason or another, can no longer be adequately absorbed by the small intestine and are instead passed into the stool. In other words, steatorrhea is the outward manifestation of fat malabsorption, an impaired ability of the digestive system to process and absorb the lipids contained in food.

In most cases, steatorrhea is associated with disorders of the pancreas, the gland responsible for producing pancreatic lipases, the enzymes that break down dietary fats into absorbable units. However, as we will explore in detail, any disruption along the fat digestion and absorption pathway, whether at the level of bile production, pancreatic enzyme secretion, or the small intestinal mucosa itself, can result in fat malabsorption and steatorrhea.

The clinical hallmark of steatorrhea is the production of pale, bulky, foul-smelling, greasy stools that characteristically float in the toilet bowl and may leave an oily film on the water surface. While these features may seem merely unpleasant, they are clinically significant: they are the visible evidence of a digestive process that is failing, and of nutritional deficiencies that, if left unaddressed, can have serious health consequences.

Steatorrhea is not a disease in and of itself. It is a symptom: a manifestation of an underlying pathological process that must be identified and, where possible, treated. This guide provides a comprehensive overview of the physiology of fat absorption, the causes of its failure, the clinical consequences, and the diagnostic and therapeutic approaches available.

How Dietary Fats Are Normally Absorbed

To understand why steatorrhea occurs, it is essential to first appreciate the normal physiology of fat digestion and absorption, a process of considerable biochemical complexity.

The Challenge of Digesting Fats

Dietary fats, primarily in the form of triglycerides, present a unique digestive challenge compared to proteins and carbohydrates. Fats are hydrophobic (water-repelling), meaning they do not dissolve in the aqueous environment of the digestive tract. If you have ever poured oil into water, you have observed this: the oil separates into droplets and refuses to mix with the water phase. The same problem exists in the gut: before fat can be digested by enzymes, it must first be made accessible in an aqueous environment.

The body solves this problem through a two-step process: emulsification followed by enzymatic hydrolysis.

Step 1: Emulsification by Bile

Bile is a complex digestive fluid produced by the liver, stored and concentrated in the gallbladder, and released into the duodenum (the first segment of the small intestine) in response to fat ingestion. Bile contains bile acids, amphipathic molecules (having both water-soluble and fat-soluble regions) that function as natural detergents.

Bile acids surround large fat droplets and break them into millions of tiny fat particles, a process called emulsification. This dramatically increases the total surface area of the fat available for enzymatic attack. An emulsion, such as milk or mayonnaise, is a stable suspension of tiny fat droplets in a water-based liquid. The bile-fat emulsion in the gut is a biological version of the same principle.

Step 2: Enzymatic Digestion by Pancreatic Lipases

Once emulsified, the fat droplets are accessible to digestive enzymes, primarily pancreatic lipase, secreted by the exocrine pancreas into the duodenum via the pancreatic duct. Pancreatic lipase, working with its cofactor colipase (also of pancreatic origin) and other lipolytic enzymes, cleaves the fatty acid chains from the triglyceride backbone. This generates free fatty acids and monoglycerides, which are small enough to be absorbed.

These products of lipase digestion are incorporated into micelles, tiny mixed aggregates of bile acids, fatty acids, monoglycerides, phospholipids, and fat-soluble vitamins, which ferry the fat products to the intestinal absorptive cells (enterocytes) of the small intestinal mucosa.

Step 3: Mucosal Absorption and Lymphatic Transport

At the surface of the intestinal epithelium, the components of the micelles are taken up by enterocytes through a combination of passive diffusion and carrier-mediated transport. Inside the enterocytes, fatty acids and monoglycerides are reassembled into triglycerides, packaged into chylomicrons (large lipoprotein particles), and secreted into the lacteals, which are lymphatic channels within the intestinal villi. From the lacteals, chylomicrons enter the lymphatic system and ultimately reach the systemic bloodstream via the thoracic duct.

The Efficiency of Normal Fat Absorption

Under normal conditions, this elegantly orchestrated process is highly efficient: more than 90% of dietary fat consumed each day is successfully absorbed. The stool of a healthy individual contains only a small amount of fat (typically less than 7 grams per day). When fecal fat excretion exceeds 7 grams per day (or, by more liberal definitions, when more than 14 grams per day is excreted), steatorrhea is clinically defined.

Any significant defect in bile secretion, pancreatic enzyme production, or intestinal mucosal integrity can reduce this efficiency and lead to steatorrhea.

Causes

The causes of steatorrhea can be systematically organized according to the step in the fat digestion-absorption process that is primarily disrupted. Three major pathophysiological categories are recognized:

Category 1: Exocrine Pancreatic Insufficiency (Absent or Inadequate Lipase Production)

Exocrine pancreatic insufficiency (EPI) is the most common cause of steatorrhea in adults in most high-income countries, and results from the pancreas’s inability to produce and/or secrete sufficient pancreatic lipase and other digestive enzymes.

Chronic pancreatitis is the most frequent cause of EPI, accounting for the majority of adult cases. Chronic pancreatitis involves progressive, irreversible inflammation and fibrosis (scarring) of the pancreatic tissue, gradually destroying the enzyme-secreting acinar cells. The most common cause of chronic pancreatitis in adults is alcohol abuse, which is responsible for approximately 70–80% of cases in Western countries. Other causes include autoimmune pancreatitis, hereditary pancreatitis, obstruction of the pancreatic duct, and idiopathic forms.

Other important causes of EPI include:

Cystic fibrosis: The most common life-limiting inherited disease in people of European descent. Mutations in the CFTR gene cause abnormally thick, viscous secretions that obstruct the pancreatic ducts. This leads to progressive pancreatic destruction and exocrine pancreatic insufficiency (EPI), which typically manifests in childhood. Steatorrhea and failure to thrive are classic early manifestations.
Obstruction of the pancreatic duct: By a tumor, gallstone, or stricture, preventing pancreatic enzymes from reaching the duodenum. The most clinically important cause of pancreatic duct obstruction is pancreatic cancer. This malignancy has a poor prognosis, and steatorrhea may be an early or presenting symptom.
Pancreatic resection: Surgical removal of part or all of the pancreas (pancreatectomy or Whipple’s procedure), performed for cancer, trauma, or chronic pancreatitis, inevitably reduces enzyme-producing capacity.
Pancreatic divisum: A congenital anatomical variant in which the main pancreatic duct drainage pathway is absent or disrupted.
Shwachman-Diamond syndrome: A rare inherited disorder causing pancreatic exocrine insufficiency, primarily in children.

Steatorrhea in EPI usually becomes clinically apparent only after more than 90% of pancreatic exocrine function has been lost. This shows the pancreas has an enormous reserve capacity.

Category 2: Bile Deficiency (Reduced Production or Secretion of Bile Acids)

When bile acids are insufficient, whether due to impaired production by the liver, obstruction of the biliary tract, or failure to reabsorb and recycle them, fat emulsification is impaired. Consequently, the fat products of lipase digestion cannot be incorporated into micelles. Even with intact pancreatic enzyme production, fat absorption fails in the absence of adequate bile.

Cholestasis (impaired bile flow) is the primary biliary cause of steatorrhea and can result from:

Primary biliary cholangitis (PBC): An autoimmune condition in which the bile ducts within the liver are progressively destroyed by an immune-mediated inflammatory process. The reduction in bile flow causes cholestasis and fat malabsorption, which can eventually lead to biliary cirrhosis.
Primary sclerosing cholangitis (PSC): A chronic inflammatory condition causing progressive fibrosis and stricturing of the intra- and extrahepatic bile ducts, leading to cholestasis and impaired bile secretion.
Common bile duct obstruction: From gallstones, biliary strictures, cholangiocarcinoma (bile duct cancer), or pancreatic head cancer obstructing the ampulla of Vater.
Hepatocellular disease: Severe liver failure from any cause (cirrhosis, acute hepatic failure, viral hepatitis) can impair bile acid synthesis and secretion.

Bile acid malabsorption (BAM) is another important mechanism, in which bile acids are not efficiently reabsorbed in the terminal ileum (the last segment of the small intestine) and are therefore lost in the stool, depleting the bile acid pool and impairing fat absorption:

Ileal resection or disease: Surgical removal of the terminal ileum (e.g., after trauma or in the treatment of inflammatory bowel disease) or disease affecting the ileal mucosa (particularly Crohn’s disease involving the terminal ileum) prevents the normal reabsorption of bile acids.
SIBO (Small Intestinal Bacterial Overgrowth): Excessive bacterial colonization of the small intestine causes premature deconjugation of bile acids. This biochemical modification prevents bile acids from forming effective micelles, which impairs fat absorption. As a result, lipase digestion products cannot be properly emulsified.

Category 3: Malabsorption Due to Small Intestinal Disease, Surgery, or Medications

Even when bile and pancreatic enzymes are both fully functional, steatorrhea can result from intrinsic disease of the small intestinal mucosa that impairs the absorption of fat digestion products, or from the administration of drugs that interfere with fat absorption.

Small intestinal mucosal diseases causing steatorrhea include:

Celiac disease: An immune-mediated enteropathy triggered by dietary gluten (found in wheat, barley, and rye) in genetically susceptible individuals. The resulting small intestinal inflammation causes villous atrophy (flattening of the finger-like projections that provide the intestinal surface area for absorption) and crypt hyperplasia. The dramatically reduced absorptive surface area leads to fat malabsorption (as well as malabsorption of other nutrients including iron, folate, vitamin B12, and calcium). Celiac disease is one of the most important and treatable causes of malabsorption in the general population.
Tropical sprue: A malabsorptive syndrome predominantly affecting individuals in tropical regions, caused by yet-unidentified infectious agents; characterized by villous atrophy similar to celiac disease but responsive to antibiotics and folate.
Giardiasis: Infection of the upper small intestine with the protozoan parasite Giardia lamblia (also called Giardia intestinalis). Giardia colonizes the duodenal and jejunal mucosa, disrupting the absorptive brush border and causing fat malabsorption. A common traveler’s infection; also associated with contaminated water supplies.
Whipple’s disease: A rare, systemic infection caused by the bacterium Tropheryma whipplei. The organism infiltrates the small intestinal mucosa and lymphatics, causing profound malabsorption. Classic features include diarrhea, steatorrhea, weight loss, and arthralgia (joint pain); the diagnosis is made by duodenal biopsy.
Intestinal lymphoma: Malignant infiltration of the small intestinal mucosa and lymphatics by lymphoma cells disrupts the normal absorptive architecture and lymphatic drainage of absorbed fat.
Amyloidosis: Deposition of amyloid protein in the intestinal wall impairs mucosal absorption.
SIBO: As noted above, SIBO contributes to fat malabsorption both through bile acid deconjugation and through mucosal inflammation and damage.
HIV enteropathy: Direct infection of the intestinal mucosa by HIV, as well as opportunistic infections affecting the gut (such as Cryptosporidium, Microsporidium, and Mycobacterium avium complex), can cause chronic steatorrhea and profound malnutrition in individuals with advanced HIV/AIDS.

Short bowel syndrome: When the small intestine undergoes extensive surgical resection (such as from Crohn’s disease, ischemic bowel, trauma, or other causes), the result is a reduction in the available absorptive surface area and transit time. This results in malabsorption of fat and multiple other nutrients.

Medications that can cause or contribute to steatorrhea include:

Orlistat (Alli®, Xenical®): A lipase inhibitor used as a weight-loss medication, which deliberately inhibits the digestion and absorption of approximately one-third of dietary fat. Steatorrhea (oily, leaking stools) is a well-known and expected side effect, particularly when fat intake is excessive.
Anion exchange resins (bile acid sequestrants, such as cholestyramine [Questran®]): Used to lower LDL cholesterol; they bind bile acids in the gut and prevent their reabsorption, depleting the bile acid pool and potentially impairing fat absorption at high doses.
Octreotide and lanreotide (somatostatin analogues): Used in the treatment of acromegaly and neuroendocrine tumors; these drugs inhibit pancreatic enzyme secretion and gallbladder motility, leading to fat malabsorption and steatorrhea.
Metformin: In some individuals, long-term metformin use has been associated with fat malabsorption, possibly through effects on bile acid metabolism.

Epidemiological Note: Most Common Cause in Adults

In adults in high-income countries, chronic pancreatitis is the most frequent underlying cause of clinically significant steatorrhea. The primary cause of chronic pancreatitis in these cases is chronic alcohol abuse. In children, cystic fibrosis and celiac disease are the most important considerations.

Symptoms

The clinical presentation of steatorrhea ranges from asymptomatic (in mild or early cases, where the condition may go entirely unnoticed) to overtly symptomatic in moderate-to-severe malabsorption. The characteristic stool abnormalities are the most specific feature.

Stool Characteristics

The hallmark features of steatorrhea are:

Pale or clay-colored stools: In normal digestion, bile pigments (bilirubin degradation products, primarily stercobilin) give stools their characteristic brown color. When bile is absent or significantly reduced, such as in biliary obstruction or severe cholestasis, stools take on a pale, gray, or chalky appearance. In EPI, the lack of lipase activity causes fat to remain in the stool, which also contributes to pallor.
Bulky, voluminous stools: The excessive fat content dramatically increases stool volume.
Greasy, oily, or waxy texture: Stools may appear to glisten or have an oily sheen, reflecting their high fat content.
Foul, rancid odor: Bacterial fermentation of unabsorbed fat produces characteristic malodorous volatile compounds.
Floating stools: The high fat content reduces stool density below that of water, causing stools to float. This is a frequently reported symptom that patients often notice spontaneously. Crucially, steatorrhea stools may be difficult or impossible to flush. They often adhere to the toilet bowl or float persistently, even after repeated flushing.
Anal oily leakage: In more severe cases, patients may notice oily anal discharge or anal staining of underwear. Some may even experience fecal incontinence, which occurs when the anal sphincter cannot contain the liquid, oily stool.

Associated Symptoms

Beyond the stool changes, patients with steatorrhea may also experience:

Abdominal discomfort and bloating from fermentation of unabsorbed nutrients.
Diarrhea: Often chronic and difficult to control.
Weight loss: Due to the significant caloric deficit created by fat malabsorption.
Symptoms of the underlying disease: Including abdominal pain (chronic pancreatitis), jaundice and pruritus (biliary disease), recurrent respiratory infections (cystic fibrosis), or dermatitis herpetiformis (celiac disease).

Complications

Persistent, untreated steatorrhea leads to a cascade of nutritional and metabolic complications that can seriously impair health and quality of life:

Malnutrition and Caloric Deficit

Dietary fat is the most calorie-dense macronutrient (9 kcal per gram, compared to 4 kcal/gram for protein and carbohydrates). When a significant fraction of dietary fat is not absorbed, the result is a substantial and persistent caloric deficit. Over time, this drives:

Progressive weight loss and generalized malnutrition.
Loss of subcutaneous fat: The body’s adipose tissue reserves are depleted as energy intake falls below requirements.
Muscle wasting (sarcopenia): In severe or prolonged cases, the body catabolizes skeletal muscle protein to meet energy needs, leading to weakness, fatigue, and further functional decline.

Impaired Growth in Children

In children and adolescents, malnutrition from steatorrhea leads to growth retardation and delayed puberty. These consequences are especially severe when the underlying cause, such as celiac disease or cystic fibrosis, remains undiagnosed or poorly managed for years. Early diagnosis and treatment are critical to preventing these long-term developmental consequences.

Fat-Soluble Vitamin Deficiencies

Perhaps the most clinically significant long-term consequence of chronic fat malabsorption is the development of deficiencies of the fat-soluble vitamins: A, D, E, and K. These vitamins are absorbed dissolved in fat micelles alongside dietary lipids; when fat absorption is impaired, their absorption is proportionally reduced.

Vitamin A deficiency: Can cause night blindness, dry eyes (xerophthalmia), and impaired immune function. Severe deficiency is a leading cause of preventable blindness worldwide.
Vitamin D deficiency: Leads to impaired calcium absorption and bone mineralization. In children, this causes rickets (softening and deformity of growing bones); in adults, it causes osteomalacia (soft bones, bone pain) and, over the long term, contributes to osteoporosis (reduced bone density and increased fracture risk).
Vitamin E deficiency: A potent antioxidant; deficiency can cause neurological abnormalities including spinocerebellar ataxia, peripheral neuropathy, and myopathy.
Vitamin K deficiency: Essential for the synthesis of clotting factors II, VII, IX, and X. Deficiency causes a bleeding diathesis, which includes easy bruising, prolonged bleeding from wounds, and, in severe cases, spontaneous hemorrhage.

Electrolyte Disturbances

Unabsorbed long-chain fatty acids can bind to calcium and magnesium in the gut (a process called saponification), preventing their absorption and leading to hypocalcemia (low blood calcium) and hypomagnesemia (low blood magnesium). Both can cause neuromuscular symptoms, such as muscle cramps and tetany. In severe cases, they may also lead to cardiac arrhythmias.

Diagnosis

Steatorrhea is a symptom, not a diagnosis. The diagnostic evaluation therefore aims to identify the underlying cause responsible for fat malabsorption. This process begins with careful clinical assessment and proceeds to targeted investigations.

Clinical Assessment: History and Physical Examination

A thorough medical history (anamnesis) and physical examination are the essential first steps and often provide the most important diagnostic clues:

Alcohol history: Chronic heavy alcohol use strongly suggests chronic pancreatitis as the underlying cause.
Family history: Cystic fibrosis follows autosomal recessive inheritance; celiac disease and inflammatory bowel disease cluster in families.
Dietary history: Onset of symptoms after introduction of gluten-containing foods in infancy suggests celiac disease; relief of symptoms on a gluten-free diet supports this.
Medication review: Orlistat, bile acid sequestrants, and somatostatin analogues should be identified.
Travel history: Travel to developing countries raises the possibility of giardiasis or tropical sprue.

Physical examination findings that may suggest specific diagnoses include:

Anemia, oral ulcers, and dermatitis herpetiformis: Extraintestinal manifestations highly characteristic of celiac disease.
Abdominal pain: A predominant feature of chronic pancreatitis (often severe, epigastric, radiating to the back); also reported in SIBO, inflammatory bowel disease, and celiac disease.
Sinopulmonary manifestations: Chronic productive cough, recurrent chest infections, and digital clubbing are characteristic of cystic fibrosis.
Jaundice, generalized pruritus, and fatigue: This triad strongly suggests hepatobiliary disease, especially cholestatic liver conditions like PBC or PS.
Signs of severe malnutrition: Loss of subcutaneous fat, muscle wasting, edema (from protein deficiency/hypoalbuminemia), and signs of specific vitamin deficiencies (e.g., easy bruising for vitamin K deficiency, bone tenderness for vitamin D deficiency).

Laboratory Investigations

A range of blood, urine, and stool tests may be ordered, guided by the clinical suspicion:

Blood tests:

Complete blood count (CBC): Anemia (iron deficiency, megaloblastic) is common in malabsorption syndromes.
Comprehensive metabolic panel: Liver function tests (ALT, AST, bilirubin, alkaline phosphatase, GGT) for hepatobiliary disease; albumin and pre-albumin as markers of nutritional status; calcium, magnesium, and phosphate for electrolyte disturbances.
Fat-soluble vitamin levels: Serum vitamins A, D, E, and K (or PT/INR as an indirect marker of vitamin K status).
Pancreatic lipase and amylase: Elevated in acute pancreatitis; may be reduced in severe chronic pancreatitis.
Anti-tissue transglutaminase IgA antibodies (anti-tTG IgA): The primary serological screen for celiac disease; highly sensitive and specific.
IgA level: To exclude selective IgA deficiency, which would give a false-negative anti-tTG IgA result.
Serum IgG4: Elevated in autoimmune pancreatitis.
Genetic testing: CFTR mutation analysis for cystic fibrosis.

Stool tests:

72-hour fecal fat quantification: The gold standard for confirming the presence and quantifying the severity of steatorrhea. The patient consumes a standardized diet containing 100 g of fat per day for three days, while all stools are collected and analyzed. Fecal fat excretion >7 g/day confirms steatorrhea. This test is cumbersome but diagnostically definitive.
Sudan staining of a random stool sample: A simpler qualitative test that microscopically identifies fat droplets in a stool smear; less precise than 72-hour collection but useful as a rapid screen.
Fecal elastase-1: Pancreatic elastase is secreted by the exocrine pancreas and measured in a single stool sample. A low level indicates exocrine pancreatic insufficiency; a simple, non-invasive, and reasonably sensitive test for EPI.
Stool culture and ova-and-parasite examination: For infectious causes, including Giardia, Cryptosporidium, and bacterial pathogens.
Fecal alpha-1-antitrypsin: A marker of protein-losing enteropathy.

Breath tests:

Hydrogen breath tests: Useful for diagnosing lactose intolerance, SIBO (glucose or lactulose breath test), and bile acid malabsorption (selenium homotaurocholic acid [SeHCAT] test, though this is a nuclear medicine test rather than a standard breath test).

Urine tests:

D-xylose absorption test: Xylose (a sugar that does not require pancreatic digestion) is administered orally and urinary excretion is measured. Normal excretion suggests intact intestinal mucosal function; reduced excretion implicates mucosal disease. This helps differentiate mucosal malabsorption from pancreatic or biliary causes.

Imaging Studies

Abdominal ultrasound: First-line imaging; useful for detecting gallstones, biliary duct dilation, pancreatic structural abnormalities (calcifications in chronic pancreatitis, masses suggesting cancer), hepatomegaly, and ascites.
CT scan of the abdomen: Provides more detailed cross-sectional anatomy; the preferred imaging modality for evaluating the pancreas (pancreatic duct dilation, parenchymal calcification, atrophy, or tumors), assessing biliary tract obstruction, and staging suspected malignancy.
MRI and MRCP (Magnetic Resonance Cholangiopancreatography): The gold standard non-invasive technique for visualizing the bile ducts and pancreatic duct; particularly useful in PSC, where it demonstrates the characteristic “beaded” appearance of the biliary tree.
Endoscopic Retrograde Cholangiopancreatography (ERCP): An endoscopic technique that provides direct visualization of the biliary and pancreatic ducts and allows therapeutic interventions (stent placement, stone removal). Used when non-invasive imaging is insufficient or intervention is required.
Endoscopic ultrasound (EUS): Provides high-resolution imaging of the pancreas and adjacent structures; superior to conventional ultrasound for detecting small pancreatic tumors and evaluating the pancreatic parenchyma in chronic pancreatitis.

Biopsies

Small intestinal biopsy (obtained via upper gastrointestinal endoscopy / gastroscopy): Essential for diagnosing celiac disease (villous atrophy, crypt hyperplasia, increased intraepithelial lymphocytes), Whipple’s disease (periodic acid-Schiff positive macrophages in the lamina propria), intestinal lymphoma, amyloidosis, and other mucosal diseases.
Liver biopsy: Indicated when liver disease is suspected as the cause of cholestasis and biliary steatorrhea, particularly to confirm PBC, PSC, or other hepatic conditions when non-invasive assessment is inconclusive.

Differential Diagnosis

A critical aspect of evaluating suspected steatorrhea is distinguishing it from other common causes of loose or frequent stools that are not caused by fat malabsorption. This distinction has important therapeutic implications. If you treat steatorrhea with approaches designed for other forms of diarrhea, the treatment will be ineffective.

The most important conditions to differentiate from steatorrhea include:

Irritable bowel syndrome (IBS): A functional disorder characterized by altered bowel habits (diarrhea-predominant, constipation-predominant, or mixed) and abdominal pain, without structural, inflammatory, or biochemical abnormality. IBS does not cause fat malabsorption; stool fat content is normal, and nutritional deficiencies do not develop. The diagnosis is clinical.
Carbohydrate malabsorption: Including lactose intolerance (deficiency of intestinal lactase, causing osmotic diarrhea after dairy consumption) and fructose malabsorption. These conditions cause loose, gassy stools after ingestion of the relevant carbohydrate, but do not involve fat malabsorption and do not cause steatorrhea.
Chronic or recurrent gastrointestinal infections: Bacterial, viral, or parasitic gastroenteritis can cause persistent diarrhea that may superficially resemble steatorrhea. Stool microscopy, culture, and molecular testing will identify the causative organism.
Inflammatory bowel disease (Crohn’s disease and ulcerative colitis): Can cause diarrhea and, particularly in Crohn’s disease with ileal involvement, some degree of fat malabsorption. However, the presence of blood in the stool, abdominal pain, and systemic inflammation (elevated CRP, raised calprotectin) help distinguish IBD from pure malabsorptive steatorrhea.
Microscopic colitis: Presents with chronic, watery, non-fatty diarrhea in older adults; diagnosed by colonic biopsies showing characteristic histological changes (collagenous or lymphocytic colitis).
Secretory diarrheas: Caused by enterotoxigenic bacteria, hormonal tumors (VIPoma, gastrinoma, carcinoid), or medications; characterized by large-volume watery stools that do not contain excess fat.

The 72-hour fecal fat test is the most definitive way to confirm the presence of fat malabsorption and distinguish steatorrhea from other causes of diarrhea.

Treatment

The treatment of steatorrhea must be directed at the underlying cause. There is no universal treatment for fat malabsorption. Instead, the therapeutic approach depends entirely on the underlying cause: whether the issue stems from the pancreas, the biliary system, or the intestinal mucosa. A shared decision-making approach, incorporating the patient’s preferences and clinical circumstances, is important.

Dietary Management

A normal or fat-enriched diet is recommended for most patients with steatorrhea, in apparent contradiction to what intuition might suggest. The rationale is as follows: although fat restriction may reduce the volume and frequency of fatty stools (because less unabsorbed fat reaches the colon), it simultaneously worsens nutritional status by further restricting caloric intake in patients who are already nutritionally compromised. The malnutrition that results from fat restriction is clinically more harmful than the steatorrhea itself.

Exceptions exist in certain specific situations, such as lymphatic disorders like intestinal lymphangiectasia or some post-surgical conditions. In these cases, restricting long-chain dietary fat and replacing it with medium-chain triglycerides (MCT) may be helpful. These MCTs are absorbed directly into the portal circulation, bypassing the need for lymphatic transport.

Supplementation of fat-soluble vitamins (A, D, E, and K) is an essential component of management in all patients with significant, chronic fat malabsorption, to prevent or treat the deficiency states described above. These supplements should be given in water-soluble forms (which do not require fat micelles for absorption) when possible.

Exocrine Pancreatic Insufficiency: Pancreatic Enzyme Replacement Therapy (PERT)

For patients with EPI, which may result from chronic pancreatitis, cystic fibrosis, pancreatic cancer, or pancreatic resection, the cornerstone of treatment is pancreatic enzyme replacement therapy (PERT).

PERT involves oral administration of pharmaceutical preparations of pancreatic enzymes. These preparations contain lipase, protease, and amylase to compensate for the body’s inadequate endogenous production. The most widely used preparation is pancrelipase (e.g., Creon®), a porcine-derived enzyme preparation available in enteric-coated microsphere capsules. The enteric coating protects the enzymes from gastric acid degradation, releasing them in the more alkaline environment of the duodenum where they can function effectively.

Key principles of PERT:

Enzymes must be taken with each meal and snack, not before or after, to ensure they are present in the duodenum at the same time as ingested fat.
Dosing is individualized based on the fat content of meals and the clinical response (stool characteristics, weight gain, vitamin levels).
Adequate acid suppression with a proton pump inhibitor (PPI) may be needed to optimize the duodenal pH for enzyme activity, particularly in patients whose acid output is increased (as in Zollinger-Ellison syndrome).
In patients with CF, PERT must be accompanied by aggressive nutritional support and fat-soluble vitamin supplementation.

SIBO: Antibiotic Therapy

When SIBO is identified as the cause or a contributing factor, treatment with targeted antibiotics is indicated to reduce the abnormal bacterial overgrowth:

Rifaximin (Normix®, Rifacol®): A non-absorbable oral antibiotic that acts locally within the gut lumen, minimizing systemic side effects. It is the most widely used antibiotic for SIBO and is well tolerated. Treatment courses are typically 10–14 days, but SIBO has a tendency to recur, and repeated courses or continuous prophylactic therapy may be needed in some patients.
Other antibiotics used include metronidazole, amoxicillin-clavulanate, and tetracycline. The choice depends on the clinical context and local resistance patterns.

Identifying and addressing any predisposing anatomical or functional factor (such as a motility disorder, structural abnormality, or immunodeficiency) is important to prevent recurrence.

Celiac Disease: Strict Gluten-Free Diet

The only effective treatment for celiac disease is a lifelong, strictly gluten-free diet. This means completely and permanently eliminating wheat, barley, and rye from what you eat. There is no pharmacological alternative; dietary adherence is the sole therapeutic option and, when maintained rigorously, leads to full mucosal recovery, resolution of malabsorption, normalization of nutritional status, and elimination of the increased long-term risks (intestinal lymphoma, osteoporosis) associated with untreated disease.

This requires dedicated dietary education (ideally with a specialist dietitian experienced in celiac disease), avoidance of cross-contamination, and regular long-term follow-up to monitor adherence and nutritional status.

Primary Biliary Cholangitis: Ursodeoxycholic Acid and Liver Transplantation

Ursodeoxycholic acid (UDCA) (Deursil®, Ursacol®, and others) is the first-line pharmacological treatment for PBC. UDCA is a naturally occurring bile acid that, when administered orally, modifies the composition of the bile acid pool toward more hydrophilic (less toxic) species, reduces biliary inflammation, and slows the progression of disease. The majority of patients respond well to UDCA, with improvement in liver biochemistry and reduced progression to cirrhosis.

However, approximately 40% of patients with PBC do not achieve an adequate biochemical response to UDCA. Second-line therapies include obeticholic acid (a farnesoid X receptor agonist) and fibrates (bezafibrate, fenofibrate). For patients who progress to end-stage liver disease despite treatment, liver transplantation is the definitive therapeutic option and is associated with excellent long-term outcomes in PBC.

Primary Sclerosing Cholangitis: Endoscopic and Surgical Intervention

Unlike PBC, PSC has no proven disease-modifying pharmacological treatment. UDCA has been studied but has not demonstrated clear benefit and is not routinely recommended. Management focuses on:

Endoscopic treatment of dominant strictures (with balloon dilatation and/or stenting) to relieve biliary obstruction.
Treatment of bacterial cholangitis (a common complication) with antibiotics.
Surveillance for cholangiocarcinoma (bile duct cancer), a major complication of long-standing PSC, and for colorectal cancer (strongly associated with PSC-IBD).
Liver transplantation: The only definitive treatment for PSC with end-stage liver disease.

Giardiasis: Antiparasitic Treatment

Giardiasis is treated with metronidazole (the most widely used first-line agent), tinidazole (a single-dose alternative), or nitazoxanide. Treatment is highly effective, with resolution of steatorrhea and other symptoms typically within 1–2 weeks.

Frequently Asked Questions

What does steatorrhea look like?

Steatorrhea produces pale (gray, white, or clay-colored), bulky, greasy, and foul-smelling stools that typically float in the toilet bowl and may be difficult to flush. In more severe cases, patients may notice oily spots on the surface of the water after defecation, or anal oil leakage.

Is steatorrhea dangerous?

Steatorrhea itself is not immediately life-threatening, but it is a sign of an underlying condition that requires diagnosis and treatment. If left untreated, chronic fat malabsorption leads to progressive malnutrition. It also causes deficiencies of fat-soluble vitamins (A, D, E, and K), muscle wasting, bone disease, and, in children, growth retardation. The severity of consequences depends on the underlying cause and the duration of untreated malabsorption.

What causes steatorrhea?

The most common causes are: exocrine pancreatic insufficiency (most often from chronic pancreatitis, most commonly caused by alcohol abuse), celiac disease, bile deficiency (from cholestatic liver disease or biliary obstruction), SIBO, Crohn’s disease involving the ileum, and medications such as orlistat.

How is steatorrhea diagnosed?

Diagnosis begins with clinical history and examination. The most definitive test is the 72-hour fecal fat collection. Other useful tests include fecal elastase-1 (for pancreatic insufficiency), anti-tTG antibodies (for celiac disease), hydrogen breath tests (for SIBO), and imaging studies (ultrasound, CT, MRI/MRCP) of the pancreas and biliary system. Small intestinal biopsy may be needed in selected cases.

Can steatorrhea be cured?

This depends entirely on the underlying cause. Celiac disease resolves completely on a strict gluten-free diet. Giardiasis is cured by antiparasitic treatment. SIBO responds to antibiotic therapy, though it may recur. Exocrine pancreatic insufficiency from chronic pancreatitis or pancreatic resection is not reversible, but the steatorrhea is effectively managed with pancreatic enzyme replacement therapy. Biliary causes may be treated medically (UDCA for PBC) or surgically (liver transplantation in end-stage disease).

Is fatty stool always steatorrhea?

Not necessarily. Occasionally, a single greasy or floating stool may occur transiently after a particularly high-fat meal and does not indicate malabsorption. True steatorrhea is persistent, associated with other symptoms, and confirmed by quantitative stool fat measurement. If you have concerns about persistent stool changes, consult your physician.

Sources and Bibliography

BMJ Best Practice – Steatorrhea
Steatorrhea – Samy A. Azer; Senthilkumar Sankararaman. StatPearls, NCBI Bookshelf (NBK541055)
Guyton AC, Hall JE. Medical Physiology. 13th ed. Philadelphia: Elsevier/Saunders; 2015.
Lomer MC. Review article: the aetiology, diagnosis, mechanisms and clinical evidence for food intolerance. Aliment Pharmacol Ther. 2015;41(3):262-75.
Lindkvist B. Diagnosis and treatment of pancreatic exocrine insufficiency. World J Gastroenterol. 2013;19(42):7258-66.
Catassi C, Fasano A. Celiac disease diagnosis: simple rules are better than complicated algorithms. Am J Med. 2010;123(8):691-3.
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017;67(1):145-172.
Bures J, Cyrany J, Kohoutova D, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol. 2010;16(24):2978-90.
Elta GH. Approach to the patient with gross gastrointestinal bleeding. In: Yamada T, ed. Textbook of Gastroenterology. 5th ed. Oxford: Wiley-Blackwell; 2009.

Steatorrhea: Symptoms, Causes, Risks, and Remedies